Second, a large multicenter study investigating the validity of the cut‐off value of each peptide autoantibody, the association between the preoperative MGMT autoantibody level and RFS would enhance the findings of the current study and provide crucial information on the utility of MGMT autoantibody levels as a prognostic marker for glioma recurrence and treatment response. The gene discussed is MGMT; the disease is central nervous system cancer.